trending Market Intelligence /marketintelligence/en/news-insights/trending/ohDVwzZy3_uLDqr9jc5JgA2 content esgSubNav
In This List

Eisai's breast cancer drug still available after rejection by UK regulator

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Eisai's breast cancer drug still available after rejection by UK regulator

Eisai Co. Ltd. said its breast cancer drug Halaven remains available despite its rejection by the U.K.'s National Institute for Health and Care Excellence for use in a different setting.

Halaven, or eribulin, is still available to treat adults with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens. NICE had rejected the drug for use in patients who had received one chemotherapy regimen, saying the treatment is not cost effective.

Eisai said it is "extremely disappointed" with the regulator's decision but will continue further dialogue with NICE.